For people who have received IV ketamine for depression, transitioning to Spravato may feel like a significant change in treatment. Both treatments involve esketamine or ketamine-related mechanisms that affect the brain’s glutamate system, but they are not administered in the same way and should not be considered interchangeable.
Spravato, or esketamine nasal spray, has specific FDA-approved indications and is administered under medical supervision. Understanding the differences can help patients know what to expect when discussing a transition with their provider.
IV ketamine and Spravato differ in formulation, route of administration, dosing, and regulatory status. Spravato contains esketamine and is administered as a nasal spray in a certified healthcare setting.
The FDA-approved uses of Spravato include treatment-resistant depression in adults and depressive symptoms associated with major depressive disorder with acute suicidal ideation or behavior, under specified conditions.
IV ketamine may be used in other clinical circumstances, but patients should not assume that previous ketamine treatment automatically makes them eligible for Spravato. A new evaluation is appropriate before beginning treatment.
Your provider will typically review your psychiatric history, previous treatments, current symptoms, medications, and response to IV ketamine. This information helps determine whether Spravato is an appropriate option.
At Scottsdale TMS & Spravato, the treatment process begins with an assessment of your medical history, current symptoms, and previous depression treatments. The clinical team can then develop a treatment plan based on your individual circumstances.
It is important to tell your provider about your previous ketamine dose, Spravato treatment frequency, side effects, and how long any improvement lasted.
Unlike IV ketamine, Spravato is self-administered as a nasal spray under direct medical supervision. Before treatment, the clinical team checks relevant health information and vital signs, including blood pressure.
After administration, patients remain in the clinic for a required observation period of at least two hours. The team monitors the patient’s response and watches for effects such as sedation, dissociation, dizziness, or changes in blood pressure.
The experience may therefore feel different from an IV ketamine session, even though both approaches involve related pharmacological pathways.
Yes. Spravato follows an established dosing schedule rather than simply continuing the exact schedule used for IV ketamine. For treatment-resistant depression, the FDA-approved schedule generally begins with twice-weekly treatment during weeks one through four, followed by less frequent administration during later phases.
Your provider may evaluate symptoms, side effects, and overall response throughout treatment. Previous IV ketamine experience can provide useful background, but it does not determine the Spravato schedule by itself.
Our Team can monitor your response throughout treatment and discuss changes in symptoms or side effects during follow-up appointments.
Spravato can temporarily affect alertness, coordination, judgment, and perception. Patients must arrange transportation home and should not drive themselves after treatment. The FDA recommends avoiding driving or operating machinery until the following day after a restful sleep.
Planning transportation ahead of time can make the transition easier. It is also helpful to allow time for rest after appointments and keep track of how you feel between sessions.
Dr. Michael Vines and the clinical team can review your progress and help determine whether the treatment approach continues to meet your needs.
Transitioning from IV ketamine to Spravato involves more than changing the method of administration. Spravato has its own eligibility requirements, dosing schedule, monitoring procedures, and safety precautions. Previous ketamine treatment can provide useful information for your provider, but an individualized assessment is still necessary.
Scottsdale TMS & Spravato provides supervised Spravato treatment with psychiatric evaluation, monitored administration, and ongoing follow-up. Discussing your previous ketamine experience, treatment response, and concerns with your provider can help you understand what the transition may involve.
Dr. Vines has practiced psychiatry in Arizona for for over 25 years and has experience working with diverse populations that include children, adolescents, adults, geriatrics, SMI patients, and the chemically dependent.
September 17, 2026
